Severe psoriasis--oral therapy with a new retinoid - PubMed (original) (raw)
Clinical Trial
Severe psoriasis--oral therapy with a new retinoid
T Fredriksson et al. Dermatologica. 1978.
Abstract
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10--9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.
Similar articles
- Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359.
Fredriksson T, Pettersson U. Fredriksson T, et al. Dermatologica. 1979;158(1):60-4. doi: 10.1159/000250744. Dermatologica. 1979. PMID: 153863 Clinical Trial. - [Treatment of psoriasis with an orally administered effective new vitamin A acid derivative. Preliminary report].
Ott F, Bollag W. Ott F, et al. Schweiz Med Wochenschr. 1975 Apr 5;105(14):439-41. Schweiz Med Wochenschr. 1975. PMID: 1091969 Clinical Trial. German. - [Treatment of psoriasis with a derivative of retinoic acid by oral route].
Viglioglia P, Barclay CA. Viglioglia P, et al. Med Cutan Ibero Lat Am. 1977;5(6):433-42. Med Cutan Ibero Lat Am. 1977. PMID: 368464 Clinical Trial. Spanish. - [Treatment of psoriasis using vitamin A, vitamin A acid and oral retinoids].
Orfanos CE, Pullmann H, Runne U, Kurka M, Strunk V, Künzig M, Dierlich E. Orfanos CE, et al. Hautarzt. 1979 Mar;30(3):124-33. Hautarzt. 1979. PMID: 374312 Review. German. - International studies of the efficacy of etretinate in the treatment of psoriasis.
Ehmann CW, Voorhees JJ. Ehmann CW, et al. J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):692-6. doi: 10.1016/s0190-9622(82)70058-1. J Am Acad Dermatol. 1982. PMID: 7040512 Review.
Cited by
- Increased physical activity promotes skin clearance, improves cardiovascular and psychological health, and increases functional capacity in patients with psoriasis.
Sheppard R, Gan WK, Onambele-Pearson GL, Young HS. Sheppard R, et al. Skin Health Dis. 2024 Aug 9;4(5):e426. doi: 10.1002/ski2.426. eCollection 2024 Oct. Skin Health Dis. 2024. PMID: 39355754 Free PMC article. - Psoriasis localization patterns in the Swiss Psoriasis Registry (SDNTT) over 11 years: an analysis by sex and age.
Birkenmaier I, Maul LV, Oyanguren I, Sorbe C, Fröhlich F, Schlapbach C, Heidemeyer K, Yawalkar N, Boehncke WH, Ring HC, Thyssen JP, Egeberg A, Micheroli R, Thomsen SF, Mainetti C, Cozzio A, Kündig TM, Levesque MP, Navarini A, Maul JT. Birkenmaier I, et al. Arch Dermatol Res. 2024 Oct 1;316(9):654. doi: 10.1007/s00403-024-03375-5. Arch Dermatol Res. 2024. PMID: 39352439 Free PMC article. - Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.
Gulliver WP, See K, Zhu B, Konicek BW, Harrison RW, McLean RR, Kerti SJ, Burge RT, Leonardi CL. Gulliver WP, et al. J Psoriasis Psoriatic Arthritis. 2023 Apr;8(2):74-82. doi: 10.1177/24755303231155118. Epub 2023 Mar 21. J Psoriasis Psoriatic Arthritis. 2023. PMID: 39296674 Free PMC article. - Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
Mease PJ, Blauvelt A, Sima AP, Beaty SW, Low R, Gomez B, Gurrola M, Lebwohl MG. Mease PJ, et al. Dermatol Ther (Heidelb). 2024 Oct;14(10):2805-2825. doi: 10.1007/s13555-024-01258-1. Epub 2024 Sep 16. Dermatol Ther (Heidelb). 2024. PMID: 39283415 Free PMC article. - Uncovering the Differences: How DLQI and WHO-5 Scores Vary in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab 100 mg vs. 200 mg?
Trovato E, Dragotto M, Capalbo E, Cartocci A, Rubegni P, Calabrese L. Trovato E, et al. J Clin Med. 2024 Sep 4;13(17):5240. doi: 10.3390/jcm13175240. J Clin Med. 2024. PMID: 39274452 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials